| 证券代码：300942 | 证券简称：易瑞生物 公告编号：2025-024 | | --- | --- | | 债券代码：123220 | 债券简称：易瑞转债 | 深圳市易瑞生物技术股份有限公司 关于持股 5%以上股东权益变动触及 1%整数倍的提示性公告 公司持股 5%以上股东王天一先生保证向本公司提供的信息内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 深圳市易瑞生物技术股份有限公司（以下简称"公司"或"本公司"）于 2025 年 3 月 19 日披露了《关于部分股东减持股份的预披露公告》（公告编号：2025- 005），持有公司股份 26,403,521 股（占公司当时总股本的 6.5866%）的股东王 天一先生计划在该公告披露之日起 15 个交易日后的 3 个月内（即 2025 年 4 月 11 日至 2025 年 7 月 10 日期间）以集中竞价或大宗交易方式减持公司股份不超 过 12,026,005 股（占公司当时总股本比例 3.0000%）。 公司于近日收到持股 5%以上股东王天一先生出具的《关于持股 5%以上股 ...

Group 1: Company Overview and Financial Performance - The company achieved a revenue of 224.25 million RMB in 2024, with the food safety rapid testing business contributing 208.51 million RMB, a year-on-year increase of 5.29% [11] - The animal diagnosis business generated 13.74 million RMB, showing a significant growth of 63.87% year-on-year [11] - The net profit attributable to shareholders was 17.12 million RMB, reflecting a substantial increase of 109.26% compared to the previous year [11] Group 2: Strategic Partnerships and Market Expansion - The partnership with Chr. Hansen is expected to generate sales of 73.06 million EUR (approximately 600.83 million RMB) from 2025 to 2029, with the 2025 sales target accounting for about 42.18% of the company's audited revenue for 2024 [5] - The collaboration aims to enhance the company's market penetration in the global dairy product sector and diversify its business into other areas such as food and beverage, agriculture, and biomedicine [4][8] Group 3: Market Trends and Growth Projections - The global food safety testing market is projected to reach 33.7 billion USD by 2028, with a compound annual growth rate (CAGR) of 8.2% [9] - The domestic animal diagnosis market is expected to grow to 13.1 billion RMB by 2025, driven by the increasing scale of livestock farming and the rising number of pets [11] Group 4: Product Development and Innovation - The company is focusing on developing automated testing solutions to enhance testing quality and efficiency, which will also drive sales of testing reagents [7][14] - The introduction of smart solutions aims to meet customer demands for automation and digital transformation in quality control [13] Group 5: Competitive Landscape - The company holds a leading position in the domestic food safety rapid testing industry, with a revenue of 209 million RMB, while the international market is dominated by established players like IDEXX and Neogen [12] - The company aims to become a world-class leader comparable to IDEXX by expanding its international presence and enhancing its product offerings [12]

Market Overview - The Shanghai Composite Index is at 3305.11 points, below the six-month moving average, with a change of 0.80% [1] - The total trading volume of A-shares is 646.819 billion yuan [1] Stocks Breaking Six-Month Moving Average - A total of 272 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Zhongcheng Technology: 14.42% deviation, with a price increase of 14.99% [1] - Oulutong: 10.01% deviation, with a price increase of 11.78% [1] - Jiusheng Electric: 9.22% deviation, with a price increase of 19.97% [1] Stocks with Smaller Deviation Rates - Stocks that have just crossed the six-month moving average with smaller deviation rates include: - Yongdong Co., Sumeida, and Yuhua Tian, which have just crossed the six-month line [1] Additional Stocks with Notable Performance - Other stocks with notable performance include: - Benlang New Materials: 8.45% deviation, with a price increase of 10.35% [1] - Quanzhu Co.: 8.00% deviation, with a price increase of 9.85% [1] - Chuanrun Co.: 7.95% deviation, with a price increase of 10.03% [1]

Group 1: Partnership Overview - The partnership with Chr.Hansen A/S (referred to as "Chr.Hansen") is significant as it is a global provider of biological solutions, particularly in the food and nutrition sectors [3] - Chr.Hansen merged with Novozymes A/S to form Novonesis, enhancing their capabilities in biological solutions [3] - Novonesis reported a revenue of approximately RMB 31.5 billion and a net profit of about RMB 2.5 billion in 2024 [3] Group 2: Financial Impact - The sales target for the partnership from 2025 to 2029 is set at €73.06 million, equivalent to approximately RMB 600.83 million, with 2025 accounting for about 42.18% of the company's audited revenue for 2024 [4] - Historical transaction amounts with Chr.Hansen were RMB 4.23 million, RMB 31.35 million, and RMB 31.43 million for the years 2022, 2023, and 2024, respectively, representing 0.62%, 12.34%, and 14.02% of the company's annual revenue [10] Group 3: Strategic Advantages - The collaboration allows for exclusive sales and distribution rights in specified regions, excluding China and a few other countries, enhancing market penetration [4] - The dual branding strategy ("BioEasy & Chr.Hansen") on product packaging is expected to strengthen both companies' market presence [4] - The partnership is anticipated to facilitate entry into new markets and diversify the company's offerings in various sectors, including veterinary medicine and agricultural testing [5][6] Group 4: Future Development Strategy - The company aims to focus on steady growth in food safety testing and expand its animal diagnostics business [7] - Plans include strengthening domestic market presence while leveraging international partnerships to enhance global market share [8] - The company intends to build a diversified customer base, targeting both government and enterprise clients in the food production sector [12][13] Group 5: Profitability Insights - The high gross margin in overseas product sales is attributed to the proprietary production of antibodies, which are crucial for food safety testing [9] - The overseas market is expected to yield higher profit margins due to lower price sensitivity [9]

Core Viewpoint - The collaboration between EasyBio and Chr. Hansen marks a significant step in the company's internationalization strategy, with a sales target of €73.06 million (over 600 million RMB) from 2025 to 2029, which is expected to positively impact the company's future performance and market presence [1][2][6]. Group 1: Contract Details - EasyBio has signed a cooperation agreement with Chr. Hansen, setting a total sales target of €73.06 million for the period from 2025 to 2029, with the first year's target accounting for approximately 42.18% of the company's 2024 revenue [1][2]. - The sales targets are structured to grow by more than 10% in the first year and 12% in subsequent years, with annual targets increasing from approximately 95 million RMB in 2025 to nearly 150 million RMB in 2029 [2]. - The contract allows Chr. Hansen exclusive rights to sell and promote EasyBio's products globally, excluding specific countries, covering various testing products related to food safety [2][4]. Group 2: Strategic Importance - The partnership is a major breakthrough in EasyBio's internationalization strategy, which has been a key driver of the company's performance since 2023 [2]. - The collaboration will utilize a dual-brand approach, enhancing EasyBio's market penetration in the global dairy product sector while leveraging Chr. Hansen's brand influence [4]. - EasyBio aims to expand its market reach and product offerings beyond dairy, exploring opportunities in various sectors such as food, agriculture, and pharmaceuticals, supported by Chr. Hansen's and Novonesis's expertise [5]. Group 3: Market Impact - The collaboration is expected to enhance EasyBio's core competitiveness and market influence, contributing to sustainable business growth [6]. - EasyBio's international sales have shown significant growth, with overseas revenue increasing by 15.92% in 2024, reaching approximately 93.33 million RMB, and the proportion of overseas revenue rising from 31.68% in 2023 to 41.62% in 2024 [5].

Core Viewpoint - The company has signed a Partnership and Distribution Agreement with Chr.Hansen A/S, targeting a total sales goal of €73.0577 million (approximately ¥601 million) for the years 2025-2029, which is expected to positively impact the company's financial status and operational performance [1] Group 1: Agreement Details - The sales target for 2025 accounts for approximately 42.18% of the company's audited revenue for 2024 [1] - The agreement allows Chr.Hansen exclusive rights to sell, distribute, and promote the company's products in designated regions [1] - The contract will be effective from June 16, 2025, and will last for five years [1] Group 2: Product Focus - The main products involved in the agreement include antibiotic residue screening tests for milk, aflatoxin M1 screening and quantitative tests, melamine, and whey adulteration tests [1] Group 3: Strategic Impact - The partnership is expected to enhance the company's core competitiveness and market influence [1]

Core Viewpoint - The company focuses on food safety rapid testing and animal diagnostics, aiming to expand its market presence both domestically and internationally through innovative products and strategic partnerships [5][10][19]. Company Overview - The company specializes in food safety rapid testing and is expanding into animal diagnostics, providing comprehensive testing solutions across various stages of the food supply chain [5][10]. - The main products include rapid test reagents, testing instruments, and related services, ensuring food safety from production to retail [6][8]. Business Segments Food Safety Rapid Testing - The company offers a range of rapid test products, including immunochromatographic test strips and ELISA kits, applicable to various food categories such as dairy, meat, and vegetables [6][7]. - The company has developed a high-throughput multi-residue testing card for pesticide residues, capable of detecting 16 types of pesticides simultaneously within 9 minutes [8][22]. Animal Diagnostics - The animal diagnostics segment is managed by a wholly-owned subsidiary, focusing on rapid testing for livestock and companion animals, including pregnancy tests and pathogen detection [10][24]. - The company aims to leverage its existing customer base in food safety to enhance sales in animal diagnostics, particularly in markets with significant livestock populations [24]. Market Strategy - The company is deepening its international strategy, targeting untapped markets in dairy product testing and other areas, with a focus on obtaining local certifications and building partnerships [19][20]. - The global market for mycotoxin testing kits is projected to reach $825.7 million by 2028, indicating significant growth potential for the company's products in this area [19]. Regulatory Environment - Increasing domestic regulations on food safety are driving demand for testing services, as companies seek to comply with stricter standards [25]. - The company is positioned to benefit from heightened consumer awareness regarding food safety, leading to increased testing requirements from food producers and retailers [25]. Technological Innovation - The company has developed an automated digital testing platform that enhances testing efficiency and reduces costs for clients, integrating data management and real-time monitoring [26]. - A new chemiluminescence technology platform allows for multi-parameter testing in a single device, streamlining the testing process and improving accuracy [27]. Financial Performance - The company has maintained a stable financial position, with no need for restating previous financial data, indicating consistent operational performance [30]. - The company has received various certifications, reflecting its commitment to quality and innovation in the testing industry [29].

东兴证券股份有限公司 关于深圳市易瑞生物技术股份有限公司 2024 年度定期现场检查报告 | 保荐机构名称：东兴证券股份有限公司 | | 被保荐公司简称：易瑞生物（股票代码 | | | | | 300942） | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 保荐代表人姓名：周磊 | 联系电话：010-66555013 | | | | | | | | | 保荐代表人姓名：付书博 | 联系电话：010-66555013 | | | | | | | | | 现场检查人员姓名：周磊、付书博 | | | | | | | | | | 现场检查对应期间：2024 年度 | | | | | | | | | | 年 月 年 月 现场检查时间：2025 4 1 日-2025 4 3 日、2025 | 年 4 | 月 16 | 日-2025 | 年 4 | 月 | 17 | 日 | | | 一、现场检查事项 | | | | | 现场检查意见 | | | | | （一）公司治理 | | 是 | | | 否 | | | 不适用 | | 现场检查手段： | | ...

一、审计意见 我们审计了深圳市易瑞生物技术股份有限公司（以下简称"易瑞生物"或 "公司"）财务报表，包括 2024 年 12 月 31 日的合并及母公司资产负债表， 2024 年度的合并及母公司利润表、合并及母公司现金流量表、合并及母公司 股东权益变动表，以及相关财务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编 制，公允反映了易瑞生物 2024 年 12 月 31 日的合并及母公司财务状况以及 2024 年度的合并及母公司经营成果和现金流量。 审 计 报 告 华兴审字[2025]24015690016号 深圳市易瑞生物技术股份有限公司全体股东： 二、形成审计意见的基础 我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告的 "注册会计师对财务报表审计的责任"部分进一步阐述了我们在这些准则下 的责任。按照中国注册会计师职业道德守则，我们独立于易瑞生物，并履行了 职业道德方面的其他责任。我们相信，我们获取的审计证据是充分、适当的， 为发表审计意见提供了基础。 三、关键审计事项 关键审计事项是我们根据职业判断，认为对本期财务报表审计最为重要 的事项。这些事项的应对以对财务报表整 ...

东兴证券股份有限公司 关于深圳市易瑞生物技术股份有限公司 2024 年度内部控制自我评价报告的核查意见 东兴证券股份有限公司（以下简称"东兴证券"或"保荐机构"）作为深圳市 易瑞生物技术股份有限公司（以下简称"易瑞生物"或"公司"）首次公开发行股 票并在创业板上市以及向不特定对象发行可转换公司债券的保荐机构，根据《证券 发行上市保荐业务管理办法》《深圳证券交易所创业板股票上市规则》《深圳证券 交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等有关法律法 规和规范性文件的要求，对《深圳市易瑞生物技术股份有限公司 2024 年度内部控 制自我评价报告》（以下简称"评价报告"）进行了核查，具体情况如下： 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有 效性，并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建立和 实施内部控制进行监督。经理层负责组织领导企业内部控制的日常运行。公司董事 会、监事会及董事、监事、高级管理人员保证本报告内容不存在任何虚假记载、误 导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制 ...